Telix Pharmaceuticals Limited (NASDAQ:TLX) shares climbed Tuesday after the company reported solid revenue growth and continued progress across its therapeutics pipeline.

Wedbush analyst David Nierengarten reiterated an Outperform rating on the stock and maintained a $22 price target, underscoring confidence in Telix’s growth trajectory.

Growth Fueled By Imaging Demand

The move follows a business update highlighting strong momentum in Telix’s Precision Medicine unit, driven by rising adoption of its imaging portfolio.

In its first-quarter 2026 update, Telix said U.S. dose volumes rose 5% quarter over quarter, reflecting sustained demand for key products, including Illuccix and Gozellix.

Revenue Growth And Guidance Reaffirmed

The radiopharmaceuticals company reported first-quarter interim sales of $230 million, up 11% sequentially. Precision Medicine revenue came in at $186 million, marking a 16% quarter-over-quarter increase.

Telix reaffirmed its fiscal 2026 revenue outlook of $950 million to $970 million, supported by ongoing product sales in approved markets and a full-year contribution from RLS.

The company also maintained its R&D spending guidance of $200 million to $240 million, tied to advancing global commercial and clinical milestones.

Pipeline Progress Adds Confidence

In March, Telix announced that Part 1 of its ProstACT global Phase 3 study met its primary endpoints. The study showed TLX591-Tx demonstrated an acceptable safety and tolerability profile, supporting its therapeutic potential.

Analyst Positioning Remains Constructive

Telix currently carries a consensus Buy rating with an average price target of $21.63.

Recent analyst actions include:

• Wedbush: Outperform, $22 target (April 7)
• H.C. Wainwright & Co.: Buy, $20 target (April 7)

Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for Telix Pharmaceuticals, highlighting its strengths and weaknesses compared to the broader market:

• Value: Weak (Score: 13.64) — Trading at a steep premium relative to peers.
• Momentum: Bullish (Score: 83/100) — Stock is outperforming the broader market.

The Verdict: Telix Pharmaceuticals’ Benzinga Edge signal reveals a growth-heavy profile, with strong momentum but a weak value ranking, indicating potential overvaluation relative to its peers.

TLX Price Action: Telix Pharmaceuticals shares were up 5.72% at $9.610 at the time of publication on Tuesday, according to Benzinga Pro data.

Image via Shutterstock